351 related articles for article (PubMed ID: 27196753)
21. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Shi Z; Tiwari AK; Shukla S; Robey RW; Kim IW; Parmar S; Bates SE; Si QS; Goldblatt CS; Abraham I; Fu LW; Ambudkar SV; Chen ZS
Biochem Pharmacol; 2009 Mar; 77(5):781-93. PubMed ID: 19059384
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
23. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
24. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Zhang DM; Shu C; Chen JJ; Sodani K; Wang J; Bhatnagar J; Lan P; Ruan ZX; Xiao ZJ; Ambudkar SV; Chen WM; Chen ZS; Ye WC
Mol Pharm; 2012 Nov; 9(11):3147-59. PubMed ID: 23046348
[TBL] [Abstract][Full Text] [Related]
25. The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
Zhang H; Patel A; Wang YJ; Zhang YK; Kathawala RJ; Qiu LH; Patel BA; Huang LH; Shukla S; Yang DH; Ambudkar SV; Fu LW; Chen ZS
Mol Cancer Ther; 2017 Jun; 16(6):1021-1030. PubMed ID: 28265007
[TBL] [Abstract][Full Text] [Related]
26. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.
Mittapalli RK; Chung AH; Parrish KE; Crabtree D; Halvorson KG; Hu G; Elmquist WF; Becher OJ
Mol Cancer Ther; 2016 May; 15(5):819-29. PubMed ID: 26883271
[TBL] [Abstract][Full Text] [Related]
27. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
[TBL] [Abstract][Full Text] [Related]
28. Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells
Zeng F; Wang F; Zheng Z; Chen Z; Wah To KK; Zhang H; Han Q; Fu L
Acta Pharm Sin B; 2020 May; 10(5):799-811. PubMed ID: 32528828
[TBL] [Abstract][Full Text] [Related]
29. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
30. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.
Liu KJ; He JH; Su XD; Sim HM; Xie JD; Chen XG; Wang F; Liang YJ; Singh S; Sodani K; Talele TT; Ambudkar SV; Chen ZS; Wu HY; Fu LW
Int J Cancer; 2013 Jan; 132(1):224-35. PubMed ID: 22623106
[TBL] [Abstract][Full Text] [Related]
31. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.
Wang F; Li D; Zheng Z; Kin Wah To K; Chen Z; Zhong M; Su X; Chen L; Fu L
J Exp Clin Cancer Res; 2020 Mar; 39(1):50. PubMed ID: 32164732
[TBL] [Abstract][Full Text] [Related]
32. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
33. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
34. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
35. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance.
Xiang QF; Wang F; Su XD; Liang YJ; Zheng LS; Mi YJ; Chen WQ; Fu LW
Cell Oncol (Dordr); 2011 Feb; 34(1):33-44. PubMed ID: 21290212
[TBL] [Abstract][Full Text] [Related]
36. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
37. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
38. The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu CP; Hung TH; Lusvarghi S; Chu YH; Hsiao SH; Huang YH; Chang YT; Ambudkar SV
Biochem Pharmacol; 2021 Jun; 188():114516. PubMed ID: 33713643
[TBL] [Abstract][Full Text] [Related]
39. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
40. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
Bhullar J; Natarajan K; Shukla S; Mathias TJ; Sadowska M; Ambudkar SV; Baer MR
PLoS One; 2013; 8(8):e71266. PubMed ID: 23967177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]